查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015173

非侵入性产前检测市场：依检测类型、技术、怀孕週数、交付方式及最终用户划分－2026年至2032年全球市场预测

Non-invasive Prenatal Testing Market by Test Type, By Technology, Gestation Period, Mode of Delivery, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，非侵入性产前检测市场价值将达到 69.3 亿美元，到 2026 年将成长至 73.6 亿美元，到 2032 年将达到 119.5 亿美元，年复合成长率为 8.10%。

主要市场统计数据
基准年 2025 69.3亿美元
预计年份：2026年 73.6亿美元
预测年份 2032 119.5亿美元
复合年增长率 (%) 8.10%

本书将临床进展、患者期望以及影响产前诊断的操作挑战交织在一起，描绘了整体情况。

受定序和生物资讯学进步以及以患者为中心的医疗保健体系的推动，非侵入性产前检测已从一种小众筛检手段发展成为产前护理的核心支柱。目前，临床医生依靠cfDNA分析来确定早期怀孕诊断方案，而准妈妈及其伴侣则希望获得更清晰的咨询和更少的侵入性选择。因此，医学界和商业相关人员正在探索一个快速变化的领域，在这个领域中，技术能力、监管和保险公司的接受度都面临着挑战​​。

技术快速成熟、检体采集分散化以及不断变化的监管预期，正在从根本上重新定义产前诊断服务的提供方式。

近年来，在技术融合和医疗服务模式转变的推动下，非侵入性产前检测（NIPT）经历了变革性的变化。次世代定序平台和更先进的生物资讯演算法拓展了检测范围，使其不再局限于常见的染色体三体，而是能够高解析度地识别更广泛的染色体异常和微缺失。同时，检测设计和检查室自动化的进步缩短了检测时间，并提高了结果的可重复性。这反过来又加快了临床决策速度，并简化了产前诊断在日常工作流程中的整合。

评估新的进口关税对产前诊断的成本结构和策略采购决策的影响，以及这些影响对营运、供应链和支付方的影响。

2025年起对部分进口检测设备、耗材和试剂征收关税，为无创产前检测的经济效益带来了新的变数。对于依赖全球供应链采购定序仪、试剂和精密光学仪器的检测实验室和设备製造商而言，关税带来的成本调整正在挤压其营业利润率，迫使其重新评估筹资策略。许多机构正在透过审查库存管理方法、与供应商谈判长期合约以及加快讨论供应链韧性和近岸外包等方式来应对这一挑战。

透过对测试类型、技术平台、怀孕阶段、分娩模式和临床最终用户进行详细的細項分析，揭示了策略机会领域。

市场区隔洞察清楚地展现了临床需求、技术能力和服务产品之间的交集，从而形成差异化的价值提案。根据检测类型，市场涵盖染色体数目异常筛检，包括三体综合征，例如13号染色体三体综合征（巴陶氏症）、18号染色体三体综合征（爱德华氏综合征）和21号染色体三体综合征（唐氏症） ；微缺失症候群，涵盖1p36缺失、22q11.2缺失（迪乔治综合征）和猫叫综合征等疾病；性染色体非整倍体，包括柯林菲特氏症综合征（XXY）、三X透纳氏症（X染色体单染性）和XYY综合征；以及用于扩大检测范围的全基因组筛检方法。每种检测类型在分析灵敏度、咨询复杂性和确认性检测流程方面都有其独特的要求，这些要求会影响检查室的配置和临床应用。

美洲、欧洲、中东和非洲以及亚太地区在区域实施模式和政策上的细微差异，决定了不同的市场进入和服务模式。

区域趋势持续影响非侵入性产前检测的普及模式、监管预期和商业策略。在美洲，成熟的报销机制、产科服务提供者较高的临床应用率以及充满活力的商业检测实验室格局，促使企业更加关注临床效用研究、与保险公司的合作以及服务差异化。该地区的新参与企业通常优先考虑与医疗系统建立合作关係，并投资提升检测能力，以满足临床需求，同时关注服务不足社区的公平获取途径。

垂直整合、检验主导差异化、策略联盟和选择性併购等因素驱动的竞争动态正在塑造产前诊断领域的企业策略。

非侵入性产前检测领域的企业竞争呈现出垂直整合、平台差异化和策略联盟并存的局面。领先的诊断公司和临床实验室正加大对检测方法检验、先进生物资讯学和拓展适应症的投资，以强化其实证医学定位。同时，仪器製造商、试剂供应商和临床服务供应商之间的合作也日益普遍，这主要是由于需要整合解决方案以降低医院系统和大规模实验室网路采用新技术的门槛。

领导企业应采取切实可行的策略重点，同时加强临床有效性、供应链韧性、支付方合作以及以患者为中心的服务模式。

产业领导企业必须采取多管齐下的策略，才能在获得商业性利益的同时，保持临床信誉。首先，投资于严谨的临床检验研究和真实世界数据（REW）项目，有助于提升企业在保险公司和临床医生中的地位，并促进指南的更广泛应用。其次，供应链多元化和加强与供应商的关係，可以降低进口关税和零件短缺带来的风险。此外，企业也应尽可能考虑近岸外包和多供应商策略，以维持业务永续营运。

我们严谨且多方面的调查方法，结合专家访谈、临床文献整合和迭代检验，为可靠的市场洞察和建议提供了支持。

本研究途径结合了对关键相关人员的访谈、对二手文献的整合以及调查方法的三角验证，以得出平衡且令人信服的结论。主要研究包括与临床遗传学家、实验室主任、产科负责人和企业高管进行结构化对话，以了解当前的实践模式、采购重点和创新蓝图。此外，还对同行评审的临床研究、监管指南和已发表的技术概述进行了系统性回顾，以检验分析表现的属性和临床效用说明的准确性。

概述如何协调技术进步、政策演变和营运韧性，以最大限度地发挥产前筛检的临床和商业性潜力。

总而言之，非侵入性产前检测生态系统正处于一个转折点，随着技术进步、检测方法创新和政策转变的交汇，临床实践和商业模式正在重塑。分析能力的提升和检体采集方法的改进扩大了检测的可及性和临床效用，而不断变化的支付方和法律规范则提高了广泛应用所需的证据门槛。这些并行的趋势为致力于提供高品质产前服务的製造商、检测实验室和医疗保健系统带来了机会和挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按检测类型分類的非侵入性产前检测市场

  • 非整倍体筛检
    • 13号染色体三体症候群（巴陶氏症）
    • 18号染色体三体综合症（爱德华氏症候群）
    • 21三体症（唐氏症）
  • 微缺失症候群
    • 1p36 缺失
    • 22q11.2缺失（迪乔治症候群）
    • 尖叫症候群
  • 性染色体非整倍体（SCA）
    • 柯林菲特氏症（XXY）
    • 三X综合征（XXX）
    • 透纳氏症（X染色体单染色单体症候群）
    • XYY综合症
  • 全基因组筛检

第九章 依技术分類的非侵入性产前检测市场

  • 利用微阵列进行分析
  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 滚动循环放大器（RCA）

第十章 依孕週分類的非侵入性产前检测市场

  • 10-17週
  • 18-23週
  • 23週或以上

第十一章 以交付方式分類的非侵入性产前检测市场

  • 家庭检体收集
  • 检测实验室提供的检测服务
  • 即时检测

第十二章 非侵入性产前检测市场：依最终用户划分

  • 诊断检查室
  • 医院
  • 专科诊所

第十三章 非侵入性产前检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 非侵入性产前检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 非侵入性产前检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国无创产前检测市场

第十七章：中国无创产前检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Group
  • BillionToOne, Inc.
  • Biora Therapeutics, Inc.
  • BioReference Laboratories, Inc.
  • Centogene NV
  • Eurofins Scientific SE
  • F.Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Igenomix SLU by Vitrolife Group
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lilac Insights Pvt. Ltd.
  • MedGenome Labs Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Ravgen Inc.
  • Sonic Healthcare USA
  • Thermo Fisher Scientific Inc.
  • Yourgene Health by Novacyt UK Holdings Limited
Product Code: MRR-036C5CF3B521

The Non-invasive Prenatal Testing Market was valued at USD 6.93 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 8.10%, reaching USD 11.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.93 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.95 billion
CAGR (%) 8.10%

Framing the modern non-invasive prenatal testing landscape by weaving together clinical advances, patient expectations, and operational challenges shaping prenatal diagnostics

Non-invasive prenatal testing has evolved from a niche screening adjunct to a central pillar of prenatal care, shaped by advances in sequencing, bioinformatics, and an increasingly patient-centric health ecosystem. Clinicians now rely on cell-free DNA analysis to inform diagnostic pathways earlier in pregnancy, while expectant parents expect clearer counseling and less invasive options. As a result, the clinical community and commercial stakeholders are navigating a rapidly changing interface where technological capability, regulatory oversight, and payer acceptance intersect.

Consequently, the landscape demands rigorous evidence generation and thoughtful integration of laboratory workflows with obstetric care. Laboratories are balancing precision and throughput, hospitals are recalibrating protocols for prenatal counseling, and specialty clinics are refining patient engagement models to reflect both clinical utility and ethical considerations. Moreover, as diagnostic sophistication increases, so does the responsibility to ensure equitable access, clarity of results, and robust post-test follow-up. This introduction frames the broader market forces and clinical imperatives that underpin the subsequent analysis and recommendations.

How rapid technological maturation, decentralization of sample collection, and evolving regulatory expectations are fundamentally redefining prenatal diagnostic care delivery

The last several years have seen transformative shifts in non-invasive prenatal testing driven by technological convergence and shifting care delivery models. Next-generation sequencing platforms and more sophisticated bioinformatic algorithms have expanded detection capabilities beyond common trisomies, enabling identification of a broader range of chromosomal abnormalities and microdeletions with increasing resolution. At the same time, improvements in assay design and laboratory automation have compressed turnaround times and improved reproducibility, allowing for faster clinical decision-making and more streamlined integration into prenatal workflows.

Simultaneously, the market is experiencing a movement toward decentralization of sample collection and patient engagement. At-home sample kits and point-of-care testing modalities are gaining traction, creating opportunities for earlier access and greater convenience, while also raising new questions around quality control, patient education, and data security. Alongside these delivery changes, regulatory bodies and payers are progressively refining coverage frameworks and evidence requirements. This regulatory maturation, together with expanded clinical validation studies, is encouraging broader clinical adoption but also raising the bar for manufacturers and laboratories in terms of clinical utility and cost-effectiveness. Taken together, these shifts are not merely incremental; they are redefining how prenatal screening is offered, interpreted, and acted upon across multiple points of care.

Evaluating the operational, supply chain, and payer-level consequences of new import tariffs that are reshaping cost structures and strategic sourcing decisions in prenatal diagnostics

The introduction of tariffs on certain imported laboratory equipment, consumables, and reagents in 2025 has introduced a new variable into the economics of non-invasive prenatal testing. For laboratories and device manufacturers that depend on global supply chains for sequencers, reagents, and precision optics, tariff-driven cost adjustments have translated into tighter operating margins and renewed scrutiny of procurement strategies. In many places, organizations have responded by revising inventory management practices, negotiating longer-term supplier contracts, and accelerating conversations around supply chain resilience and nearshoring.

Beyond immediate cost pressures, tariffs have catalyzed strategic thinking around localization of manufacturing and diversification of component sourcing. Companies with vertically integrated operations or those able to substitute domestically produced inputs have gained relative operational flexibility. In addition, the tariff environment has prompted greater collaboration between manufacturers and payers to reassess reimbursement constructs, as stakeholders align on how to preserve patient access without compromising clinical quality. Finally, the policy environment underscores the importance of transparent cost communication and proactive regulatory engagement to mitigate downstream effects on testing availability, laboratory consolidation, and innovation trajectories.

Granular segmentation analysis linking assay types, technology platforms, gestational timing, delivery models, and clinical end-users to reveal strategic opportunity zones

Insight into market segmentation clarifies where clinical need, technological capability, and service delivery intersect to create differentiated value propositions. Based on test type, the market is organized around aneuploidy screening that includes trisomies such as Trisomy 13 (Patau Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 21 (Down Syndrome), microdeletion syndromes that cover conditions like 1p36 Deletion, 22q11.2 Deletion (DiGeorge Syndrome), and Cri-du-chat Syndrome, sex chromosome aneuploidies encompassing Klinefelter Syndrome (XXY), Triple X Syndrome (XXX), Turner Syndrome (Monosomy X), and XYY Syndrome, as well as whole-genome screening approaches that expand the detection envelope. Each test type imposes distinct requirements for analytical sensitivity, counseling complexity, and confirmatory workflows, which in turn influence laboratory architecture and clinical adoption.

From a technology standpoint, the competitive dynamics revolve around microarray-based analysis, next-generation sequencing, polymerase chain reaction techniques, and rolling circle amplification methods. Technologies differ not only in analytical throughput and cost per sample but also in bioinformatic complexity and validation expectations, thereby guiding purchasing priorities and partnership strategies. Considering gestation period, segmentation across 10-17 weeks, 18-23 weeks, and above 23 weeks shapes clinical utility, since earlier testing enables different counseling and management options compared with later gestational windows. Mode of delivery segmentation across at-home sample collection, laboratory-based testing services, and point-of-care testing highlights divergent operational models and patient experience trade-offs. Finally, end-user segmentation that includes diagnostic laboratories, hospitals, and specialty clinics captures how testing volumes, clinical pathways, and service level expectations vary, thereby affecting sales channels, payer interactions, and clinical education strategies. Integrated analysis across these segments reveals where innovation and commercial focus can yield the greatest clinical and economic impact.

Regional adoption patterns and policy nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and service models

Regional dynamics continue to shape adoption patterns, regulatory expectations, and commercial strategies in non-invasive prenatal testing. In the Americas, mature reimbursement frameworks, high clinical adoption among obstetric providers, and a dynamic landscape of commercial laboratories drive a focus on clinical utility studies, payer engagement, and service differentiation. Market participants in this region often prioritize partnerships with healthcare systems and investments in rapid laboratory throughput to meet clinical demand while simultaneously addressing concerns around equitable access in underserved communities.

Conversely, Europe, Middle East & Africa presents a heterogeneous environment where regulatory regimes and payer models vary significantly by country, prompting tailored evidence generation and market entry approaches. In several European markets, centralized public healthcare systems emphasize cost-effectiveness and national guideline alignment, while in parts of the Middle East and Africa, infrastructure and access constraints necessitate strategies centered on capacity-building and clinician education. Meanwhile, Asia-Pacific reflects a mixture of rapid adoption in urban centers, growing private lab networks, and increasing investments in local manufacturing and genomics capabilities. In this region, early-mover providers are prioritizing localization of services, multilingual patient engagement, and collaborations with regional health authorities to scale access. Across all regions, cross-border collaborations, data privacy considerations, and the need for culturally appropriate counseling remain recurrent themes that companies must navigate thoughtfully.

Competitive dynamics driven by vertical integration, validation-led differentiation, strategic partnerships, and selective consolidation shaping corporate strategies in prenatal diagnostics

Competitive behavior among companies active in non-invasive prenatal testing is characterized by a mix of vertical integration, platform differentiation, and strategic partnerships. Leading diagnostics firms and clinical laboratories are investing in assay validation, bioinformatics refinement, and expanded clinical indications to strengthen evidentiary positioning. At the same time, collaborations between instrument manufacturers, reagent suppliers, and clinical service providers are becoming more common as organizations seek to bundle solutions that reduce implementation friction for hospital systems and large laboratory networks.

In parallel, smaller innovators are carving niche positions by focusing on at-home collection platforms, enhanced patient reporting interfaces, or specialized microdeletion panels. Consolidation activity is evident as market participants pursue acquisitions to secure intellectual property, expand geographic footprints, or accelerate entry into adjacent testing modalities. Importantly, regulatory compliance and third-party accreditation remain differentiators; companies that demonstrate rigorous clinical validation, transparent performance characteristics, and robust quality systems typically gain preferential consideration from institutional purchasers and payers. Overall, the competitive landscape rewards those that combine scientific rigor with scalable operations and a clear pathway to reimbursement.

Practical strategic priorities for diagnostic leaders to strengthen clinical validation, supply resilience, payer engagement, and patient-centric delivery models concurrently

Industry leaders must adopt a multi-pronged set of actions to sustain clinical credibility while capturing commercial upside. First, investing in rigorous clinical validation studies and real-world evidence programs will strengthen positioning with payers and clinicians and will facilitate broader guideline adoption. Second, diversifying supply chains and building stronger vendor relationships will mitigate exposure to import tariffs and component shortages, and firms should evaluate nearshoring or multi-supplier strategies where feasible to preserve operational continuity.

Third, organizations should prioritize patient-centric delivery models that improve access and comprehension, including expansion of at-home collection programs coupled with clinician-mediated counseling pathways. Fourth, strengthening payer engagement through evidence-based value dossiers and outcomes data will be critical to securing sustainable reimbursement. Concurrently, companies should pursue scalable automation in laboratories and invest in interoperable data systems to reduce turnaround times and lower per-test operational costs. Finally, consider strategic partnerships or targeted M&A to obtain missing capabilities-whether in bioinformatics, sample collection, or regional market access-thereby accelerating time to market and minimizing execution risk. These recommendations create an operational playbook that balances clinical rigor with commercial pragmatism.

A rigorous, multi-source research methodology combining expert interviews, clinical literature synthesis, and iterative validation to underpin credible market insights and recommendations

The research approach integrates primary stakeholder interviews, secondary literature synthesis, and methodological triangulation to ensure balanced, defensible conclusions. Primary research involved structured conversations with clinical geneticists, laboratory directors, obstetric leaders, and commercial executives to capture contemporary practice patterns, procurement priorities, and innovation roadmaps. These insights were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and published technical briefs to validate analytical performance attributes and clinical utility narratives.

Data were cross-checked through iterative validation sessions with subject-matter experts to refine assumptions about laboratory workflows, technology adoption hurdles, and regional policy implications. Qualitative findings were further contextualized with vendor product literature and operational case studies to highlight practical implementation considerations. Finally, methodological safeguards included transparency around inclusion criteria, a clear audit trail for expert inputs, and sensitivity checks on interpretative conclusions to ensure that recommendations remain robust across plausible market scenarios.

Concluding synthesis of how technological advances, policy evolution, and operational resilience must be aligned to realize the full clinical and commercial potential of prenatal screening

In summary, the non-invasive prenatal testing ecosystem stands at an inflection point where technological advances, delivery innovations, and policy shifts converge to reshape clinical practice and commercial models. Enhanced analytical capabilities and novel modes of sample collection are expanding access and clinical utility, while evolving payer and regulatory frameworks are raising the evidence threshold for broad adoption. These parallel developments create both opportunity and complexity for manufacturers, laboratories, and health systems seeking to deliver high-quality prenatal care.

As stakeholders respond to operational pressures such as tariff-induced cost adjustments and supply chain vulnerabilities, those who invest in evidence generation, supply resilience, and patient-centered delivery will be better positioned to lead. The path forward requires coordinated action across clinical, commercial, and policy fronts to ensure that advances in non-invasive prenatal testing translate into meaningful improvements in prenatal care, equitable access, and informed decision-making for families.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-invasive Prenatal Testing Market, by Test Type

  • 8.1. Aneuploidy Screening
    • 8.1.1. Trisomy 13 (Patau Syndrome)
    • 8.1.2. Trisomy 18 (Edwards Syndrome)
    • 8.1.3. Trisomy 21 (Down Syndrome)
  • 8.2. Microdeletion Syndromes
    • 8.2.1. 1p36 Deletion
    • 8.2.2. 22q11.2 Deletion (DiGeorge Syndrome)
    • 8.2.3. Cri-du-chat Syndrome
  • 8.3. Sex Chromosome Aneuploidies (SCA)
    • 8.3.1. Klinefelter Syndrome (XXY)
    • 8.3.2. Triple X Syndrome (XXX)
    • 8.3.3. Turner Syndrome (Monosomy X)
    • 8.3.4. XYY Syndrome
  • 8.4. Whole-Genome Screening

9. Non-invasive Prenatal Testing Market, by By Technology

  • 9.1. Microarray-Based Analysis
  • 9.2. Next-Generation Sequencing (NGS)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. Rolling Circle Amplification (RCA)

10. Non-invasive Prenatal Testing Market, by Gestation Period

  • 10.1. 10-17 Week
  • 10.2. 18-23 Week
  • 10.3. Above 23 Week

11. Non-invasive Prenatal Testing Market, by Mode of Delivery

  • 11.1. At-Home Sample Collection
  • 11.2. Laboratory-Based Testing Services
  • 11.3. Point-of-Care Testing

12. Non-invasive Prenatal Testing Market, by End-User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Non-invasive Prenatal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-invasive Prenatal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-invasive Prenatal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Non-invasive Prenatal Testing Market

17. China Non-invasive Prenatal Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BGI Group
  • 18.7. BillionToOne, Inc.
  • 18.8. Biora Therapeutics, Inc.
  • 18.9. BioReference Laboratories, Inc.
  • 18.10. Centogene N.V.
  • 18.11. Eurofins Scientific SE
  • 18.12. F.Hoffmann-La Roche Ltd.
  • 18.13. GE HealthCare Technologies Inc.
  • 18.14. Igenomix S.L.U by Vitrolife Group
  • 18.15. Illumina, Inc.
  • 18.16. Labcorp Holdings Inc.
  • 18.17. Laboratory Corporation of America Holdings
  • 18.18. Lilac Insights Pvt. Ltd.
  • 18.19. MedGenome Labs Ltd.
  • 18.20. Myriad Genetics, Inc.
  • 18.21. Natera, Inc.
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. Ravgen Inc.
  • 18.24. Sonic Healthcare USA
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. Yourgene Health by Novacyt UK Holdings Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 179. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 206. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 215. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 217. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 234. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)